Emergent BioSolutions annonce la prolongation de la durée de vie du vaporisateur nasal NARCAN® au Canada
22 juil. 2024 08h00 HE
|
Emergent Biosolutions, Inc.
Le fait de porter à quatre ans la durée de vie du vaporisateur nasal NARCAN® contribue à améliorer l’accès à la naloxone dans un contexte où les communautés sont toujours aux prises avec une hausse...
Emergent BioSolutions Announces Shelf-Life Extension for NARCAN® Nasal Spray in Canada
22 juil. 2024 08h00 HE
|
Emergent BioSolutions
The extension to a four-year shelf-life helps improve naloxone access as communities continue to grapple with the growing opioid epidemic; product with the extended shelf life has officially begun...
Emergent BioSolutions Continues to Drive Improved Financial Position as Part of Multi-Year Transformation Plan
09 juil. 2024 07h30 HE
|
Emergent BioSolutions
GAITHERSBURG, Md., July 09, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today highlights several recent advancements in improving its financial health, marked by robust cash...
Update: Emergent BioSolutions Awarded $250+ Million in Contract Modifications to Supply U.S. Government with Four Critical Medical Countermeasure Products
02 juil. 2024 09h43 HE
|
Emergent BioSolutions
GAITHERSBURG, Md., July 02, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced it has received more than $250 million in contract modifications from the Administration...
Emergent BioSolutions Awarded $250+ Million in Contract Modifications to Supply U.S. Government with Four Critical Medical Countermeasure Products
02 juil. 2024 08h13 HE
|
Emergent BioSolutions
GAITHERSBURG, Md., July 02, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced it has received more than $250 million in contract modifications from the Administration...
Emergent BioSolutions Announces Sale of Baltimore-Camden Manufacturing Site to Bora Pharmaceuticals for $30 Million
20 juin 2024 07h00 HE
|
Emergent BioSolutions
GAITHERSBURG, Md., June 20, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that it has entered into a definitive agreement to sell its drug product facility in...
Emergent BioSolutions Continues Driving Progress Against the Opioid Epidemic & Recognizes National Naloxone Awareness Day
06 juin 2024 09h02 HE
|
Emergent BioSolutions
Naloxone is a medication that rapidly reverses the effects of opioid overdose and is the standard of care for opioid overdose reversal in a community settingNew topline survey findings reinforce the...
Emergent BioSolutions to Hold Virtual Annual Meeting of Stockholders on Thursday, May 23, 2024
10 mai 2024 07h17 HE
|
Emergent BioSolutions
GAITHERSBURG, Md., May 10, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that its 2024 Annual Meeting of Stockholders will be held in a virtual-only format via live...
Emergent BioSolutions Reports First Quarter 2024 Financial Results
01 mai 2024 16h57 HE
|
Emergent BioSolutions
First Quarter 2024 Total Revenues of $300.4 million, above the prior guidance rangeFirst Quarter 2024 Net Income of $9.0 million and Adjusted EBITDA of $66.9 millionUpdates FY 2024 guidance ...
Emergent BioSolutions Announces Strategic Operational Changes to Stabilize Financial Position
01 mai 2024 16h10 HE
|
Emergent BioSolutions
Proactive changes aim to ensure long-term sustainability and growth, optimize operations, streamline processes, and allocate resources more efficientlyReorganization will align with evolving business...